Glenmark Pharma launches India's first Triple-Drug Combo for type 2 Diabetes

Glenmark Pharmaceuticals Ltd saw a rise in its shares during morning trading on October 18, following the announcement of its launch of a triple-drug fixed-dose combination (FDC) comprising Teneligliptin, Dapagliflozin, and Metformin. This combination targets type 2 diabetes in adults with comorbidities, making Glenmark the first company in India to introduce this treatment. Taken once daily under prescription, the drug enhances glycemic control in type 2 diabetes patients.

 

Priced at Rs 14 per tablet, this product is expected to reduce daily therapy costs by 30%. Marketed under the name Zita DM, it contains DPP4 inhibitor Teneligliptin (20mg), SGLT2 inhibitor Dapagliflozin (10mg), and Metformin SR (500mg/1000mg) in a fixed dose.

 

Alok Malik, President and Business Head – India Formulations at Glenmark Pharma, expressed pride in the introduction of Zita DM. He emphasized that it offers an effective and economical solution for adult patients dealing with high HbA1c levels and other comorbidities, while also reducing significant renal and cardiac adverse events.

 

Glenmark reported that its Zita line of medicines annually supports approximately 1.75 million type 2 diabetic patients in India. According to IQVIA sales data from the 12 months ending August 2023, the market for oral anti-diabetic drugs in the country is estimated at Rs 12,522 crore, reflecting a 6.5% yearly growth.

Top stories
Company

Delta Corp Q1 PAT Declines 68% YoY to Rs 22 crore in FY25

4 mins read . 13 Jul 2024 . 09:30 AM

Company

Zydus Life Gets USFDA Nod for Heart Failure Drug

3 mins read . 13 Jul 2024 . 09:23 AM

Company

RVNL Spurts 10% on Bagging Multiple Orders Worth Rs 390 Cr

4 mins read . 13 Jul 2024 . 09:18 AM

Related Blogs
blog-logo

Share Market

blog-logo

12 mins read . 12 Jul 2024

Ritesh Agarwal: The OYO Founder’s Success Story

  • 0 people read
blog-logo

Share Market

blog-logo

15 mins read . 08 Jul 2024

Best Oil & Gas Stocks in India

  • 0 people read
Kickstart your equities journey today You've got this
By submitting this I agree to the terms & conditions